ICER assessing efgartigimod and eculizumab for myasthenia gravis News item 20 March 2021 Pages: 1 - 1
ICER's final report on roxadustat: net health benefit not demonstrated News item 20 March 2021 Pages: 3 - 3
AEs impact cost effectiveness of smoking cessation therapies Clinical study 20 March 2021 Pages: 4 - 4
Andexanet "low value" for reversal of factor Xa-associated intracranial haemorrhage Clinical study 20 March 2021 Pages: 5 - 5
Apixaban lower risk of adverse outcomes, lower cost in non-valvular AF + CAD/PAD Clinical study 20 March 2021 Pages: 6 - 6
Atezolizumab + nab-paclitaxel not cost effective in advanced PD-L1-positive triple-negative breast cancer Non-clinical study 20 March 2021 Pages: 7 - 7
Australians willing to accept short-term restrictions during pandemic Clinical study 20 March 2021 Pages: 8 - 8
Behavioural smoking-cessation counselling during pregnancy worth extra cost Clinical study 20 March 2021 Pages: 9 - 9
Cabozantinib may be cost effective in advanced renal cell carcinoma Clinical study 20 March 2021 Pages: 10 - 10
Can next-generation sequencing reduce costs in clinical practice? Non-clinical study 20 March 2021 Pages: 11 - 11
Cost-effectiveness framework for evaluating COVID-19 therapies Clinical study 20 March 2021 Pages: 12 - 12
Coverage expansion for non-invasive prenatal testing: clinical benefits, modest budget increase Non-clinical study 20 March 2021 Pages: 13 - 13
Early drug pricing agreements lower break-even price of orphan drugs Clinical study 20 March 2021 Pages: 14 - 14
Empagliflozin highly cost-effective treatment option for patients with T2DM and CVD Clinical study 20 March 2021 Pages: 15 - 15
Home-based rapid SARS-CoV-2 antigen testing reduces transmission, saves lives at reasonable cost Non-clinical study 20 March 2021 Pages: 16 - 16
Hospitals' diversity of diagnosis groups driver of costs of care Non-clinical study 20 March 2021 Pages: 17 - 17
Immunisation campaign using oral cholera vaccine Shanchol cost effective in Malawi Clinical study 20 March 2021 Pages: 18 - 18
Intrauterine levonorgestrel cost effective for preventing cancer Clinical study 20 March 2021 Pages: 19 - 19
Is extension of HPV vaccination to adults up to age 45 years in the US good value for money? Non-clinical study 20 March 2021 Pages: 20 - 20
Is PET-CT-guided management a cost-effective option in early oral-cavity cancer? Clinical study 20 March 2021 Pages: 21 - 21
New method for comparing cost of care to identify high-value cancer care Non-clinical study 20 March 2021 Pages: 22 - 22
Postnatal depression: substantial cost, major inequalities in Australia Clinical study 20 March 2021 Pages: 23 - 23
Quantifying the cost of chemotherapy administration: review of the literature Review 20 March 2021 Pages: 24 - 24
Requests for branded drugs increase US Medicare expenditure Clinical study 20 March 2021 Pages: 25 - 25
Reviewing cost-effectiveness evidence for phosphate binders in hyperphosphataemia in CKD Review 20 March 2021 Pages: 26 - 26
Scaling up investment in cancer care would yield economic benefits Clinical study 20 March 2021 Pages: 27 - 27
Small changes to CHEERS criteria may increase modelling acceptance Clinical study 20 March 2021 Pages: 28 - 28
TKI discontinuation cost saving in patients with CML in remission Clinical study 20 March 2021 Pages: 30 - 30
Treatment-related severe oral mucositis increases cancer costs Clinical study 20 March 2021 Pages: 31 - 31
Universal COVID-19 vaccination cost saving unless anaphylaxis rate high Clinical study 20 March 2021 Pages: 32 - 32